Form D · Biotechnology
Sonnet BioTherapeutics Holdings, Inc.
Princeton, NJ · CIK 0001106838
Offering snapshot reported Dec 23, 2024 · SEC filing
- Reported sold
- $3.92M Offering amount: $3.92M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 23, 2024 | Initial | $3,918,000 | No comparison | 4 | SEC filing |
| Jul 17, 2023 | Initial | $2,250,000 | No comparison | 1 | SEC filing |
| Aug 19, 2022 | Initial | $2,250,000 | No comparison | 5 | SEC filing |
| May 16, 2018 | Initial | $1,411,249 | No comparison | 13 | SEC filing |
| May 11, 2017 | Initial | $6,000,000 | No comparison | 14 | SEC filing |
| Mar 18, 2015 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jan 16, 2015 | Initial | $1,150,000 | No comparison | 12 | SEC filing |
| Nov 20, 2013 | Initial | $800,000 | No comparison | 3 | SEC filing |
| Oct 22, 2013 | Initial | $2,500,000 | No comparison | 23 | SEC filing |
| Oct 15, 2013 | Initial | $0 | No comparison | 193 | SEC filing |
| Aug 13, 2013 | Initial | $3,000,000 | No comparison | 7 | SEC filing |
| Nov 30, 2011 | Initial | $1,125,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $379K
- Finders' fees
- $0
- Form D file number
- 021-533167
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Chardan Capital Markets, LLC | 000120128 |
Source: Form D, filed Dec 23, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rich Adams | Executive |
| Nailesh Bhatt | Director |
| Michael Carroll | Director |
| John K. Cini | Executive |
| Brian Corbman | Director |
| Jay Cross | Executive |
| Susan Dexter | Executive |
| Albert Dyrness | Director |
| Donald Griffith | Director |
| Keith J. Johnson | Director |
| Richard Kenny | Executive |
| Neil C. Kiefer | Director |
| Gregory E. Kraut | Director |
| Eric Lederer | Executive |
| Lori Mc Neil | Director |
| Pankaj Mohan | Director, Executive |
| Paul Moskowitz | Director |
| David P. Osborn | Director |
| Russell J. Page | Director |
| Michael D. Pruitt | Director, Executive, Promoter |
| Raghu Rao | Director |
| Mark Roberson | Executive |
| Larry S. Spitcaufsky | Executive |
| J. Eric Wagoner | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Overlook Cetner Suite 102
Princeton, NJ, 08540
Princeton, NJ, 08540